- Home
- SKYE vs ECBK Comparison
SKYE vs ECBK Comparison
Compare SKYE & ECBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKYE
- ECBK
- Stock Information
- Founded
- SKYE 2012
- ECBK 1919
- Country
- SKYE United States
- ECBK United States
- Employees
- SKYE N/A
- ECBK N/A
- Industry
- SKYE Biotechnology: Pharmaceutical Preparations
- ECBK Banks
- Sector
- SKYE Health Care
- ECBK Finance
- Exchange
- SKYE Nasdaq
- ECBK Nasdaq
- Market Cap
- SKYE 108.3M
- ECBK 134.8M
- IPO Year
- SKYE N/A
- ECBK N/A
- Fundamental
- Price
- SKYE $2.70
- ECBK $15.05
- Analyst Decision
- SKYE Buy
- ECBK
- Analyst Count
- SKYE 6
- ECBK 0
- Target Price
- SKYE $18.67
- ECBK N/A
- AVG Volume (30 Days)
- SKYE 193.9K
- ECBK 6.9K
- Earning Date
- SKYE 02-09-2025
- ECBK 10-24-2024
- Dividend Yield
- SKYE N/A
- ECBK N/A
- EPS Growth
- SKYE N/A
- ECBK N/A
- EPS
- SKYE N/A
- ECBK 0.39
- Revenue
- SKYE N/A
- ECBK $24,711,000.00
- Revenue This Year
- SKYE N/A
- ECBK N/A
- Revenue Next Year
- SKYE N/A
- ECBK N/A
- P/E Ratio
- SKYE N/A
- ECBK $38.54
- Revenue Growth
- SKYE N/A
- ECBK N/A
- 52 Week Low
- SKYE $2.25
- ECBK $11.39
- 52 Week High
- SKYE $19.41
- ECBK $15.75
- Technical
- Relative Strength Index (RSI)
- SKYE 25.41
- ECBK 49.93
- Support Level
- SKYE $3.21
- ECBK $14.67
- Resistance Level
- SKYE $3.55
- ECBK $15.37
- Average True Range (ATR)
- SKYE 0.40
- ECBK 0.29
- MACD
- SKYE -0.08
- ECBK -0.04
- Stochastic Oscillator
- SKYE 1.93
- ECBK 35.19
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
About ECBK ECB Bancorp Inc.
ECB Bancorp Inc operates as a bank holding company of Everett Co-operative Bank. The firm through its subsidiary engages in business consisting of taking deposits from the general public and investing those deposits, together with funds generated from operations, in one- to four-family residential real estate loans, commercial real estate, and multifamily real estate loans, construction and land loans and home equity lines of credit.